Skip to main content
Saudi Journal of Medicine & Medical Sciences logoLink to Saudi Journal of Medicine & Medical Sciences
. 2024 Jun 20;12(3):266–269. doi: 10.4103/sjmms.sjmms_629_23

Hemorrhagic Shock from Acute Variceal Bleeding Caused by Sarcoidosis: A Case Report

Mark Evert Haaksma 1, Sjoerd van der Bie 1, Ellert J van Soest 2, Ben Vermin 1, Marco Goeijenbier 1,3,✉
PMCID: PMC11268539  PMID: 39055077

Abstract

Sarcoidosis is a disease of unknown etiology, characterized by noncaseating granulomas. Generally, the condition primarily manifests in the lungs. Extrapulmonary involvement is common, but localization in the gastrointestinal system is rare. Here, we present the case of a 37-year-old male who became increasingly hemodynamically unstable during the diagnostic workup for sarcoidosis due to acute variceal bleeding. The underlying mechanism was later attributed to portal hypertension caused by hepatic involvement of the disease. This case demonstrates the importance of considering variceal hemorrhage as a rare but life-threatening complication of gastrointestinal localization of sarcoidosis.

Keywords: Extrapulmonary sarcoidosis, upper gastrointestinal tract, portal hypertension, sarcoidosis, shock, variceal bleeding

INTRODUCTION

Sarcoidosis is a systemic inflammatory disease that can affect any part of the human body and is characterized by the occurrence of noncaseating granulomas. To date, its etiology is unknown. While pulmonary involvement is most common (in up to 90% of cases), gastrointestinal involvement is rare (in <10% of the cases).[1,2] Cirrhosis and portal hypertension can be clinical manifestations in <1% of cases;[3] however, given the low frequency of these complications, they may be easily missed by the treating physician. Here, we describe a rare case of variceal bleeding and hemorrhagic shock due to hepatic involvement of sarcoidosis in a young male patient.

The CARE Checklist was followed by the authors while preparing this case report.

CASE REPORT

A 37-year-old male presented to the emergency department with dyspnea and left thoracic pain that exacerbated on inspiration. He did not have fever, night sweats, cough, palpitations, or chest pain on exertion. Prior medical history only revealed mild liver chemistry disturbances, which at the time were attributed to his recent weight gain.

Bloodwork revealed no signs of inflammation, mildly elevated calcium, and elevated lactate dehydrogenase. Given the high suspicion for pulmonary pathology, thoracic CT was performed. It revealed diffuse pulmonary consolidation [Figure 1], splenomegaly, and calcification of lymph nodes throughout the entire body. Under the strong suspicion of sarcoidosis, sIL-2R was tested and a positron emission tomography–computed tomography (PET-CT) was performed. With a value of 24,530 pg/ml, sIL2r was strongly elevated, while the PET-CT demonstrated disseminated metabolic activity in the lungs, liver, spleen, lymph nodes, and bone marrow [Figure 2]. The patient was scheduled for diagnostic excision of an axillary lymph node. Further bloodwork revealed pan-hypopituitarism, potentially through cerebral localization of sarcoidosis, for which hydrocortisone was started as the first step of the treatment process.

Figure 1.

Figure 1

Transverse chest computed tomography showing diffusely consolidated lung tissue

Figure 2.

Figure 2

Positron emission tomography–computed tomography demonstrating disseminated metabolic activity in lungs, liver, spleen, lymph nodes and bone marrow

After an uncomplicated lymph node excision, the patient became progressively hypotensive and passed melena. He was admitted to the ICU under suspicion of an ulcerative bleed and was started on vasopressor therapy and continuous proton pump inhibitor infusion. Extensive laboratory analysis was performed [Table 1]. The following day, gastroscopy was performed and revealed an actively bleeding varix [Figure 3], upon which the procedure was ended to prepare for intubation before proceeding. During pre-oxygenation, the patient started to repeatedly vomit large amounts of blood. After a failed attempt to place a Sengstaken balloon, continuous suction briefly provided improved visibility, which allowed for successful intubation. Subsequently, the gastroscopy was continued, and actively bleeding varices could be ligated. During the procedure, four units of packed red cells, four units of fresh frozen plasma, four units of thrombocytes, 1000 cc 0.9% sodium chloride, and 2g of calcium gluconate were transfused [Table 1]. The patient was started on ceftriaxone prophylaxis and continuous octreotide and pantoprazol perfusion.

Table 1.

Bloodwork at admission and directly after variceal bleed

Parameters Reference values At admission After variceal bleed
Hemoglobin 8.5–11.0 mmol/L 4.3 6.2
Hematocrit 0.40–0.50 L/L 0.21 0.28
Platelets 150–400×109/L 159
Leukocytes 4.0–10.0×109/L 18.8 19.6
Factor I (fibrinogen) 2.0–4.0 g/L 1.0
APTT 22–30 s 25
INR 0.95–1.17 1.4
pH (art) 7.35–7.45 7.42 7.41
PO2 (art) 10.0–13.3 kPa 10.0 17.9
PCO2 (art) 4.7–6.4 kPa 3.7 4.9
Bicarbonate (art) 21.0–28.0 mmol/L 18.2 23.5
Base excess −3.0–3.0 mmol/L −5.7 −0.9
Sodium 135–145 mmol/L 148 155
Potassium 3.5–5.1 mmol/L 4.4 3.5
Chloride 96–107 mmol/L 122 126
Urea 2.5–6.4 mmol/L 8.9 8.9
Creatinine 64–104 umol/L 78 72
eGFR (CKD-EPI) >60 mL/min/1.73 m2 >90 >90
Bilirubin total 3–20 umol/L 8
Gamma GT 0–55 IU/L 106
Alkaline phosphatase 0–115 IU/L 582
ASAT 0–35 U/L 121
ALAT 0–45 U/L 38
LD 0–248 U/L 355
CK 0–171 U/L 28
Albumin 35–55 g/L 20.5
Calcium 2.15–2.55 mmol/L 1.74
Magnesium 0.70–1.00 mmol/L 0.84 0.91
Phosphate 0.70–1.50 mmol/L 0.82 0.98
Lactate 0.5–1.7 mmol/L 6.1 1.5
Glucose 3.5–7.8 mmol/L 5.3 8.4

APTT – Activated partial thromboplastin time; INR – International normalized ratio; eGFR – Estimated glomerular filtration rate; CKD-EPI – Chronic kidney disease-epidemiology collaboration; GT – Glutamyl transferase; ASAT – Aspartate amino transferase; ALAT – Alanine amino transferase; CK – Creatine kinase; LD – Lactate dehydrogenase

Figure 3.

Figure 3

Left image: Endoscopy of the esophagus with severe active bleeding. Right image: Endoscopy of the esophagus showing a ligated varix

After three days, the patient remained hemodynamically stable and he was extubated. A week later he was discharged. Follow-up and subsequent treatment were to occur at a tertiary academic hospital, given the severity and complexity of the disease, with yet-to-be confirmed but suspected cerebral localization of granulomas. Later, a histological diagnosis of sarcoidosis was made.

DISCUSSION

The present case illustrates the importance of recognizing extrapulmonary manifestations of sarcoidosis, especially those of the gastrointestinal system that result in portal hypertension and acute upper gastrointestinal variceal bleeds. Including this rare but potentially fatal complication of sarcoidosis in the differential diagnosis of a hemodynamically unstable patient with a prior history of the disease could lead to earlier identification, treatment, and safer intervention. As such, we aimed to summarize the pathophysiology of variceal bleeding in patients with sarcoidosis and provide a brief outline of the current treatment recommendations.

Sarcoidosis can manifest anywhere in the body including, although less frequently, the gastrointestinal system. An even more rare occurrence is cirrhosis and portal hypertension as consequences of hepatic involvement of the disease. The underlying pathophysiology is not fully understood, with several hypotheses postulated, of which the most straightforward is through the obstruction of hepatic venous outflow by granulomas, similar to the mechanism of portal hypertension in cirrhosis. However, there is also evidence for the presence of arteriovenous shunts within the granulomas potentially also contributing to the rise of portal pressure.[4] Another hypothesis is that granulomas in the portal circuit restrict flow, and thus increase presinusoidal pressure.[5] Regardless of the exact cause, the final common pathway is elevation in the portal venous system, which leads to an increase in esophageal vein size, and subsequently, risk for spontaneous bleeds from them.

Fast and deliberate treatment is vital, given the poor prognosis of patients with variceal hemorrhage. The first step is securing the airway to prevent aspiration. Hemodynamic instability is initially treated with bolus infusions of isotonic crystalloids. Transfusion strategy in severe ongoing bleeding is identical to trauma patients in a 1:1:1 ratio for red blood cells, plasma, and platelets.[6] This remains the case even in the presence of disturbed coagulation panels, as they are poorly representative of true hemostatic balance given variable pro- and anticoagulant effects of cirrhosis.[7] Subsequent permissive hypotension and avoidance of volume overload are important to reduce the risk of rebound portal hypertension and rebleeding.[8,9]

Pharmacological intervention in upper GI bleeds includes proton pump inhibitors, antibiotics, somatostatin (analogs), and less frequently, vasopressin (analogs). While proton pump inhibitors have not been proven to improve clinical outcomes in cirrhosis, current guidelines still advocate their use in treating patients with hypothesized upper gastrointestinal bleeding of still unknown cause.[10] In proven variceal hemorrhage, they have no role.[11] Prophylactic antibiotics are the only option that reduce overall mortality, rebleed, and infections, and thus should be administered as soon as possible.[12] Typically, ceftriaxone is the antibiotic of choice for a duration of up to 7 days. Somatostatin (analogs) prevent rebleeding and help achieve hemostasis, but have no proven benefit on mortality.[13] Vasopression (analogs) have potent vasoconstrictive properties on the splanchnic system, but are considered third-line therapeutic regime given the increased frequency of adverse events. Endoscopic treatment consists of ligation of bleeding varices. If prompt endoscopy is not possible, balloon tamponade devices, such as the Sengstaken or Linton tube can be used.

The disease progression of hepatic sarcoidosis is poorly documented and highly variable. This entails that treatment indication, its timing, and choice of therapeutic drug are just as unclear. To date, no randomized controlled trials are available that compare agents and their efficacy. As such, current treatment strategies are based on retrospective studies.

The available evidence suggests that corticosteroids generally form the first line of treatment, typically started around 20–40 mg prednisone daily.[14] Other treatment options include antimetabolites (e.g., azathioprine and methotrexate), alkylating agents (e.g., cyclophosphamide) biologic agents (e.g., infliximab) or a combination of these with corticosteroids.[15,16] The goal of the treatment is to limit sarcoidosis-related symptoms and to prevent disease progression and loss of hepatic function. Whether normalization of liver chemistry disturbances during treatment is related to better long-term outcomes is unclear.

CONCLUSION

Variceal hemorrhage is a rare but life-threatening complication of gastrointestinal localization of sarcoidosis. It should be considered in the differential diagnosis of patients presenting with upper gastrointestinal bleeding.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Peer review

This case report was peer-reviewed by two independent and anonymous reviewers.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

  • 1.Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper D, et al. 14th. New York, New York, United States: McGraw-Hill; 1997. Harrison’s Principles of Internal Medicine; p. 1406. [Google Scholar]
  • 2.Vardhanabhuti V, Venkatanarasimha N, Bhatnagar G, Maviki M, Iyengar S, Adams WM, et al. Extra-pulmonary manifestations of sarcoidosis. Clin Radiol. 2012;67:263–76. doi: 10.1016/j.crad.2011.04.018. [DOI] [PubMed] [Google Scholar]
  • 3.Blich M, Edoute Y. Clinical manifestations of sarcoid liver disease. J Gastroenterol Hepatol. 2004;19:732–7. doi: 10.1111/j.1440-1746.2003.03335.x. [DOI] [PubMed] [Google Scholar]
  • 4.Maddrey WC, Johns CJ, Boitnott JK, Iber FL. Sarcoidosis and chronic hepatic disease: A clinical and pathologic study of 20 patients. Medicine (Baltimore) 1970;49:375–95. doi: 10.1097/00005792-197009000-00002. [DOI] [PubMed] [Google Scholar]
  • 5.Mistilis SP, Green JR, Schiff L. Hepatic sarcoidosis with portal hypertension. Am J Med. 1964;36:470–5. [Google Scholar]
  • 6.Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: Implications of new concepts for perioperative management. Transfus Med Rev. 2014;28:107–13. doi: 10.1016/j.tmrv.2014.03.002. [DOI] [PubMed] [Google Scholar]
  • 7.Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147–56. doi: 10.1056/NEJMra1011170. [DOI] [PubMed] [Google Scholar]
  • 8.Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368:11–21. doi: 10.1056/NEJMoa1211801. [DOI] [PubMed] [Google Scholar]
  • 9.Cerqueira RM, Andrade L, Correia MR, Fernandes CD, Manso MC. Risk factors for in-hospital mortality in cirrhotic patients with oesophageal variceal bleeding. Eur J Gastroenterol Hepatol. 2012;24:551–7. doi: 10.1097/MEG.0b013e3283510448. [DOI] [PubMed] [Google Scholar]
  • 10.Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;2010:CD005415. doi: 10.1002/14651858.CD005415.pub2. [DOI] [PubMed] [Google Scholar]
  • 11.Gralnek IM, Camus Duboc M, Garcia-Pagan JC, Fuccio L, Karstensen JG, Hucl T, et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2022;54:1094–120. doi: 10.1055/a-1939-4887. [DOI] [PubMed] [Google Scholar]
  • 12.Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;2010:CD002907. doi: 10.1002/14651858.CD002907.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Gøtzsche PC, Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2008 2008 Jul 16;(3):CD000193. doi: 10.1002/14651858.CD000193.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Beegle SH, Barba K, Gobunsuy R, Judson MA. Current and emerging pharmacological treatments for sarcoidosis: A review. Drug Des Devel Ther. 2013;7:325–38. doi: 10.2147/DDDT.S31064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sedki M, Fonseca N, Santiago P, Diaz L, Garcia-Buitrago M, Mirsaeidi M, et al. Hepatic sarcoidosis: Natural history and management implications. Front Med (Lausanne) 2019;6:232.. doi: 10.3389/fmed.2019.00232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Graf C, Arncken J, Lange CM, Willuweit K, Schattenberg JM, Seessle J, et al. Hepatic sarcoidosis: Clinical characteristics and outcome. JHEP Rep. 2021;3:100360.. doi: 10.1016/j.jhepr.2021.100360. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Saudi Journal of Medicine & Medical Sciences are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES